# Epoetin Alfa in Advanced Non-Small Cell Lung Cancer (EPO-CAN-20)

> **NCT00310232** · PHASE3 · TERMINATED · sponsor: **Ontario Clinical Oncology Group (OCOG)** · enrollment: 70 (actual)

## Conditions studied

- Non-Small-Cell Lung Carcinoma
- Lung Cancer
- Anemia

## Interventions

- **DRUG:** Epoetin Alfa

## Key facts

- **NCT ID:** NCT00310232
- **Lead sponsor:** Ontario Clinical Oncology Group (OCOG)
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2001-02
- **Primary completion:** —
- **Final completion:** 2004-04
- **Target enrollment:** 70 (ACTUAL)
- **Why stopped:** Recommendation of DSMB for safety issue, increased mortality with study drug.
- **Last updated:** 2024-04-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00310232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00310232, "Epoetin Alfa in Advanced Non-Small Cell Lung Cancer (EPO-CAN-20)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00310232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*